Latest Ratios: P/E Ratio -31.9x · EV/EBITDA N/A · ROE -28.9%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $82.1B | $11.5B | $16.0B | $38.0B | $74.7B | $109.5B | $39.8B | $6.5B | $5.0B | — | — |
| Enterprise Value | $81.4B | $10.8B | $14.8B | $36.3B | $72.7B | $103.5B | $37.5B | $6.4B | $4.4B | — | — |
| P/E Ratio → | -31.88 | — | — | — | 8.94 | 8.98 | — | — | — | — | — |
| P/S Ratio | 32.50 | 5.90 | 4.99 | 5.55 | 3.96 | 6.17 | 49.59 | 107.47 | 37.17 | — | — |
| P/B Ratio | 9.30 | 1.33 | 1.46 | 2.74 | 3.91 | 7.74 | 15.56 | 5.51 | 3.28 | — | — |
| P/FCF | — | — | — | — | 16.31 | 8.21 | 20.33 | — | — | — | — |
| P/OCF | — | — | — | — | 15.00 | 8.04 | 19.65 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.55 | 4.62 | 5.30 | 3.85 | 5.84 | 46.62 | 105.75 | 32.55 | — | — |
| EV / EBITDA | — | — | — | — | 7.44 | 7.65 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 7.57 | 7.78 | — | — | — | — | — |
| EV / FCF | — | — | — | — | 15.87 | 7.76 | 19.11 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.3% | 55.3% | 54.2% | 31.5% | 71.3% | 85.2% | 95.1% | 48.5% | 81.6% | 90.0% | 86.1% |
| Operating Margin | -158.1% | -158.1% | -123.3% | -61.9% | 49.9% | 75.0% | -95.0% | -906.4% | -347.1% | -130.9% | -206.4% |
| Net Profit Margin | -145.2% | -145.2% | -111.3% | -68.8% | 44.3% | 68.8% | -93.0% | -853.7% | -284.8% | -124.3% | -199.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -28.9% | -28.9% | -28.8% | -28.6% | 50.3% | 146.1% | -40.0% | -38.0% | -35.7% | -34.9% | -25.7% |
| ROA | -21.3% | -21.3% | -21.9% | -21.3% | 33.1% | 76.2% | -16.7% | -28.9% | -25.3% | -20.5% | -15.3% |
| ROIC | -26.1% | -26.1% | -27.0% | -21.7% | 55.8% | 237.8% | -91.9% | -41.4% | -49.8% | -30.8% | -20.9% |
| ROCE | -27.6% | -27.6% | -28.9% | -23.3% | 51.7% | 143.8% | -34.7% | -34.3% | -35.6% | -25.1% | -17.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.07 | 0.09 | 0.06 | 0.06 | 0.09 | 0.11 | 0.02 | 0.03 | 0.01 |
| Debt / EBITDA | — | — | — | — | 0.12 | 0.07 | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | -0.11 | -0.12 | -0.10 | -0.42 | -0.93 | -0.09 | -0.41 | -0.19 | -0.04 |
| Net Debt / EBITDA | — | — | — | — | -0.21 | -0.44 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -0.44 | -0.44 | -1.22 | — | — | — | -1.12 |
| Interest Coverage | -276.80 | -276.80 | -149.29 | -102.74 | 331.17 | 739.06 | -74.31 | -76.85 | -141.12 | -1938.36 | — |
Net cash position: cash ($2.6B) exceeds total debt ($1.9B)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.29 | 3.29 | 3.67 | 3.42 | 2.73 | 1.76 | 1.43 | 7.89 | 7.02 | 4.09 | 6.68 |
| Quick Ratio | 3.22 | 3.22 | 3.62 | 3.36 | 2.54 | 1.60 | 1.42 | 7.89 | 7.02 | 4.09 | 6.68 |
| Cash Ratio | 2.92 | 2.92 | 3.18 | 2.85 | 2.01 | 1.18 | 1.05 | 7.71 | 6.83 | 3.95 | 6.50 |
| Asset Turnover | — | 0.16 | 0.23 | 0.37 | 0.73 | 0.72 | 0.11 | 0.04 | 0.07 | 0.19 | 0.08 |
| Inventory Turnover | 5.67 | 5.67 | 12.51 | 23.23 | 5.71 | 1.82 | 0.83 | — | — | — | — |
| Days Sales Outstanding | — | 53.32 | 67.55 | 57.62 | 32.58 | 68.39 | 639.69 | 98.80 | 82.65 | 32.64 | 60.45 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 11.2% | 11.1% | — | — | — | — | — |
| FCF Yield | — | — | — | — | 6.1% | 12.2% | 4.9% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 3.0% | 4.5% | 0.8% | 0.0% | 0.0% | 0.2% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 3.0% | 4.5% | 0.8% | 0.0% | 0.0% | 0.2% | — | — |
| Shares Outstanding | — | $389M | $384M | $382M | $416M | $431M | $381M | $331M | $329M | $376M | $64M |
Includes 30+ ratios · 10 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MRNA stock.
Moderna, Inc.'s current P/E ratio is -31.9x. The historical average is 9.0x.
Moderna, Inc.'s return on equity (ROE) is -28.9%. The historical average is -6.4%.
Based on historical data, Moderna, Inc. is trading at a P/E of -31.9x. Compare with industry peers and growth rates for a complete picture.
Moderna, Inc. has 55.3% gross margin and -158.1% operating margin.
Key Metrics
Top Statement Risk
Commercial revenue volatility and cash burn
Metrics are mathematically derived from official filings.
Premium Multiples Price Platform Optionality
Based on reported figures, Moderna trades at a price-to-sales ratio of 42.27 and a price-to-book of 12.10 despite a trailing P/E of -41.47, indicating the market is pricing future platform value rather than current earnings power.
With trailing earnings negative, the P/E multiple is not meaningful as a valuation anchor, and the 42.27 P/S ratio implies investors are capitalizing a revenue base that has contracted roughly 39% on a trailing basis. The 12.10 price-to-book multiple, against equity that has fallen from $11.9B to $6.8B, suggests the premium rests on the optionality of the mRNA library and pipeline rather than on tangible balance sheet value. Investors should monitor whether pipeline catalysts such as intismeran can justify this premium before the cash balance is further depleted.
Quarterly Rebound Fails to Repair Trailing Losses
As reported in quarterly filings, Moderna's Q3 2026 net margin of 12.3% contrasts with a trailing net margin of -145.2% and an operating margin of -158.1%, leaving the one-quarter improvement unconfirmed as a sustained trend.
The gross margin swung from 15.9% in 2025Q1 to 75.8% in 2026Q3, which points to a revenue base highly sensitive to volume and inventory timing rather than stable unit economics. A single quarter of positive net margin, set against fixed R&D and manufacturing costs that remain elevated, may reflect a seasonal or one-time benefit rather than structural recovery. Earnings quality should be assessed after stripping out milestone and collaboration revenue before inferring a durable inflection.
Debt Step-Up Erodes Coverage Cushion
Based on reported balance sheet figures, Moderna's debt-to-equity ratio rose from 0.19 to 0.61 within a single quarter, while the debt-to-EBITDA ratio of 21.11 signals thin earnings coverage of obligations.
The jump in leverage from $1.3B to $4.2B of total debt occurred while equity was contracting, which suggests the balance sheet is being financed rather than rebuilt by operations. A debt-to-EBITDA of 21.11 and an interest coverage ratio that is not meaningfully positive indicate limited earnings capacity to service the new obligations. The terms, maturity profile, and any covenant conditions of this borrowing are not disclosed in the provided data and warrant further investigation.
Current Ratio Masks Thinning Cash Runway
According to the reported balance sheet, Moderna's current ratio of 3.62 and quick ratio of 3.47 appear comfortable, yet cash declined from $2.6B to $1.2B against a free cash flow margin of -122.3%.
High current and quick ratios are driven largely by the cash and receivable base, which is being consumed at a rapid pace by operating and capital needs. The gap between the strong ratio readings and the shrinking absolute cash position suggests the liquidity cushion may be less durable than the headline metrics imply. Under a prolonged period of negative free cash flow, the balance could compress meaningfully, so investors should monitor quarterly cash burn against available liquidity.
Working Capital Ratios Misread Business Model
The current ratio is most commonly misapplied to Moderna because it treats pandemic-era inventory and receivables as stable liquidity, obscuring write-down and obsolescence risk in a shrinking vaccine demand base.
For a company whose revenue was historically tied to government advance purchase agreements, the current ratio can overstate liquidity when inventory is at risk of write-down, as reflected in the days inventory outstanding of 86 days and the high DIO in prior periods. A better lens is free cash flow runway, measured as cash divided by quarterly cash burn, adjusted for non-cash inventory charges. This alternative captures the real survival horizon that the current ratio fails to reflect.